Chloroquine |
Penetration and uncoating inhibitors |
Interfering the glycosylation of ACE2 or alkalizing the phagolysosome of SARS-CoV-2 to inhibit the penetration of virus. |
Arbidol |
Penetration and uncoating inhibitors |
Suppressing the fusion of virus lipid membrane and host cells. |
Camostat mesylate |
Penetration and uncoating inhibitors |
Interfering the S protein priming to inhibit the penetration of virus. |
Remdesivir |
biosynthesis inhibitors |
Inhibiting the RNA-dependent RNA polymerase activity of SARS-CoV-2. |
Sofosbuvir |
biosynthesis inhibitors |
Inhibiting the RNA-dependent RNA polymerase activity of SARS-CoV-2. |
Ribavirin |
biosynthesis inhibitors |
Inhibiting the RNA-dependent RNA polymerase activity of SARS-CoV-2. |
Lopinavir/Ritonavir |
biosynthesis inhibitors |
Inhibiting the 3-chymotrypsin-like protease activity of SARS-CoV-2. |
Convalescent plasma |
Virus neutralizer |
Neutralizing the virus in body fluids to decrease the quantity of SARS-CoV-2. |
Monoclonal antibody |
Virus neutralizer |
Neutralizing the virus in body fluids to decrease the quantity of SARS-CoV-2. |
IFNs |
Antiviral therapy and improving immunity |
Inducing cells to synthesize antiviral proteins and activating natural killer cells, T cells, and macrophages to inhibit viruses. |